Prof. Garth began his neurosurgical career at the Royal Free Hospital School of Medicine in London, UK. Then, he attended Specialist Training in Neurosurgery in Glasgow’s prestigious Institute of Neurological Sciences, Glasgow, UK, where he carried out the first Polarographic Oxygen measurements in Human Brain tumours during surgery, followed by other work related to our understanding of hypoxia in brain cancer. Data from these studies lead to the trial of Tirapazamine as a hypoxic sensitizer for radiotherapy. In 1993, When he became a Senior Lecturer in Neurosurgery, he worked with Prof. Moira Brown on the use of the Oncolytic Herpes Virus directly injected into the human genome for the first time. In 1997, Prof. Garth became a Consultant Neurologist at the University of Birmingham and Queen Elizabeth Hospitals, UK. He also worked with the NCRI (National Cancer Research Institute) and EANO (European Association of Neuro-oncology), developing services for brain tumour patients as well as several clinical trials, most recently the new Immunotherapy vaccine trial ‘STING’. He worked on novel treatments such as biologically targeted radiation therapy. He has also been working closely with basic scientists on new therapeutic approaches in target discovery and drug delivery, as well as carrying out progressive surgery for brain and skull base tumours. Prof. Garth has served on editorial boards in the council of BNOG (Bristol Neuro-Oncology Group) and the NCRI (National Cancer Research Institute) Clinical Studies Group. For many years he was deeply involved in the commissioning of cancer services and continued on the Cancer Services Committee of the RCS (Royal College of Surgeons) as SBNS (Society of British Neurological Surgeons) representative. He chairs the Driver and Vehicle licensing agency Neurology Medical Panel 'DVLA neurology' and is also the Lead Clinician on the NICE Primary Brain Tumors and Cerebral Metastases clinical guidelines development program due to publish in late 2018. Currently, he is the President of Brain Tumor Research Scientific and Medical Advisory Board (SMAB) as well as a member of the European Association of Neuro-oncology (EANO).